Active, Not Recruiting
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
NCT05732805
- Conditions
- Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Melanoma (Skin), +16 more
- Locations
-
- Healthcare Institution "Bobruisk Interdistrict Oncological Dispensary" Babruysk, Belarus
- Healthcare Institution "Brest Regional Oncological Dispensary" Brest, Belarus
- Health care institution "Grodno University Clinic" Grodno, Belarus
- Health Institution "Gomel Regional Clinical Oncology Center" Homyel, Belarus